Literature DB >> 9808554

Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation.

P Carayon1, J Marchand, D Dussossoy, J M Derocq, O Jbilo, A Bord, M Bouaboula, S Galiègue, P Mondière, G Pénarier, G L Fur, T Defrance, P Casellas.   

Abstract

Two subtypes of G-protein-coupled cannabinoid receptors have been identified to date: the CB1 central receptor subtype, which is mainly expressed in the brain, and the CB2 peripheral receptor subtype, which appears particularly abundant in the immune system. We investigated the expression of CB2 receptors in leukocytes using anti-CB2 receptor immunopurified polyclonal antibodies. We showed that peripheral blood and tonsillar B cells were the leukocyte subsets expressing the highest amount of CB2 receptor proteins. Dual-color confocal microscopy performed on tonsillar tissues showed a marked expression of CB2 receptors in mantle zones of secondary follicles, whereas germinal centers (GC) were weakly stained, suggesting a modulation of this receptor during the differentiation stages from virgin B lymphocytes to memory B cells. Indeed, we showed a clear downregulation of CB2 receptor expression during B-cell differentiation both at transcript and protein levels. The lowest expression was observed in GC proliferating centroblasts. Furthermore, we investigated the effect of the cannabinoid agonist CP55,940 on the CD40-mediated proliferation of both virgin and GC B-cell subsets. We found that CP55,940 enhanced the proliferation of both subsets and that this enhancement was blocked by the CB2 receptor antagonist SR 144528 but not by the CB1 receptor antagonist SR 141716. Finally, we observed that CB2 receptors were dramatically upregulated in both B-cell subsets during the first 24 hours of CD40-mediated activation. These data strongly support an involvement of CB2 receptors during B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808554

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  Endocannabinoids and immune regulation.

Authors:  Rupal Pandey; Khalida Mousawy; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Pharmacol Res       Date:  2009-04-07       Impact factor: 7.658

3.  Recreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men.

Authors:  Chun Chao; Lisa P Jacobson; Frank J Jenkins; Donald Tashkin; Otoniel Martínez-Maza; Michael D Roth; Leslie Ng; Joseph B Margolick; Joan S Chmiel; Zuo-Feng Zhang; Roger Detels
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

Review 4.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

Review 5.  Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.

Authors:  Sreemanti Basu; Bonnie N Dittel
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

Review 6.  Endocannabinoid signalling in innate and adaptive immunity.

Authors:  Valerio Chiurchiù; Luca Battistini; Mauro Maccarrone
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

7.  Neuromolecular Mechanisms of Cannabis Action.

Authors:  Yousra Adel; Stephen P H Alexander
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.

Authors:  Jenny L Wilkerson; Sudeshna Ghosh; Mohammed Mustafa; Rehab A Abdullah; Micah J Niphakis; Roberto Cabrera; Rafael L Maldonado; Benjamin F Cravatt; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2016-11-25       Impact factor: 5.250

9.  Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro.

Authors:  L S Whyte; L Ford; S A Ridge; G A Cameron; M J Rogers; R A Ross
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 10.  CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies.

Authors:  A Arévalo-Martín; D García-Ovejero; O Gómez; A Rubio-Araiz; B Navarro-Galve; C Guaza; E Molina-Holgado; F Molina-Holgado
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.